# Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)

> **NCT01224782** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 994 (actual)

## Conditions studied

- Chronic Kidney Disease
- Secondary Hyperparathyroidism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01224782
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 994 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01224782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01224782, "Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01224782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*